147 related articles for article (PubMed ID: 12564979)
1. ATTEMPTS: a heparin/protamine-based triggered release system for the delivery of enzyme drugs without associated side-effects.
Park YJ; Liang JF; Song H; Li YT; Naik S; Yang VC
Adv Drug Deliv Rev; 2003 Feb; 55(2):251-65. PubMed ID: 12564979
[TBL] [Abstract][Full Text] [Related]
2. ATTEMPTS: a heparin/protamine-based prodrug approach for delivery of thrombolytic drugs.
Liang JF; Park YJ; Song H; Li YT; Yang VC
J Control Release; 2001 May; 72(1-3):145-56. PubMed ID: 11389993
[TBL] [Abstract][Full Text] [Related]
3. ATTEMPTS: a heparin/protamine-based delivery system for enzyme drugs.
Liang JF; Li YT; Song H; Park YJ; Naik SS; Yang VC
J Control Release; 2002 Jan; 78(1-3):67-79. PubMed ID: 11772450
[TBL] [Abstract][Full Text] [Related]
4. Construction and characterization of a t-PA mutant for use in ATTEMPTS: a drug delivery system for achieving targeted thrombolysis.
Yang VC; Naik SS; Song H; Dombkowski AA; Crippen G; Liang JF
J Control Release; 2005 Dec; 110(1):164-76. PubMed ID: 16260060
[TBL] [Abstract][Full Text] [Related]
5. A prodrug approach for delivery of t-PA: construction of the cationic t-PA prodrug by a recombinant method and preliminary in vitro evaluation of the construct.
Song H; Liang JF; Yang VC
ASAIO J; 2000; 46(6):663-8. PubMed ID: 11110262
[TBL] [Abstract][Full Text] [Related]
6. 15 years of ATTEMPTS: a macromolecular drug delivery system based on the CPP-mediated intracellular drug delivery and antibody targeting.
Ye J; Shin MC; Liang Q; He H; Yang VC
J Control Release; 2015 May; 205():58-69. PubMed ID: 25483423
[TBL] [Abstract][Full Text] [Related]
7. ATTEMPTS system: a macromolecular prodrug strategy for cancer drug delivery.
Huang Y; Park YS; Wang J; Moon C; Kwon YM; Chung HS; Park YJ; Yang VC
Curr Pharm Des; 2010 Jul; 16(21):2369-76. PubMed ID: 20618157
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and characterization of positively charged tPA as a prodrug using heparin/protamine-based drug delivery system.
Liang JF; Li YT; Connell ME; Yang VC
AAPS PharmSci; 2000; 2(1):E7. PubMed ID: 11741223
[TBL] [Abstract][Full Text] [Related]
9. A novel approach for delivery of enzyme drugs: preliminary demonstration of feasibility and utility in vitro.
Liang JF; Li YT; Yang VC
Int J Pharm; 2000 Jul; 202(1-2):11-20. PubMed ID: 10915922
[TBL] [Abstract][Full Text] [Related]
10. Preparation and characterization of anionic oligopeptide-modified tissue plasminogen activator for triggered delivery: an approach for localized thrombolysis.
Absar S; Choi S; Ahsan F; Cobos E; Yang VC; Kwon YM
Thromb Res; 2013 Mar; 131(3):e91-9. PubMed ID: 23269380
[TBL] [Abstract][Full Text] [Related]
11. Application of "ATTEMPTS" for drug delivery.
Naik SS; Liang JF; Park YJ; Lee WK; Yang VC
J Control Release; 2005 Jan; 101(1-3):35-45. PubMed ID: 15588892
[TBL] [Abstract][Full Text] [Related]
12. The ATTEMPTS delivery systems for macromolecular drugs.
Kwon YM; Li Y; Naik S; Liang JF; Huang Y; Park YJ; Yang VC
Expert Opin Drug Deliv; 2008 Nov; 5(11):1255-66. PubMed ID: 18976135
[TBL] [Abstract][Full Text] [Related]
13. A novel heparin/protamine-based pro-drug type delivery system for protease drugs.
Liang JF; Song H; Li YT; Yang VC
J Pharm Sci; 2000 May; 89(5):664-73. PubMed ID: 10756332
[TBL] [Abstract][Full Text] [Related]
14. PTD-Modified ATTEMPTS for Enhanced Toxin-based Cancer Therapy: An In Vivo Proof-of-Concept Study.
Shin MC; Zhang J; Min KA; He H; David AE; Huang Y; Yang VC
Pharm Res; 2015 Aug; 32(8):2690-703. PubMed ID: 25701313
[TBL] [Abstract][Full Text] [Related]
15. Modified dextran, heparin-based triggered release microspheres for cardiovascular delivery of therapeutic drugs using protamine as a stimulus.
Nguyen HX; O'Rear EA
J Microencapsul; 2017 May; 34(3):299-307. PubMed ID: 28436713
[TBL] [Abstract][Full Text] [Related]
16. PTD-modified ATTEMPTS system for enhanced asparaginase therapy: a proof-of-concept investigation.
Kwon YM; Li YT; Liang JF; Park YJ; Chang LC; Yang VC
J Control Release; 2008 Sep; 130(3):252-8. PubMed ID: 18652856
[TBL] [Abstract][Full Text] [Related]
17. Advances in antibody-directed enzyme prodrug therapy.
Sharma SK; Bagshawe KD; Begent RH
Curr Opin Investig Drugs; 2005 Jun; 6(6):611-5. PubMed ID: 15997480
[TBL] [Abstract][Full Text] [Related]
18. Zein-Paclitaxel Prodrug Nanoparticles for Redox-Triggered Drug Delivery and Enhanced Therapeutic Efficiency.
Hou H; Zhang D; Lin J; Zhang Y; Li C; Wang Z; Ren J; Yao M; Wong KH; Wang Y
J Agric Food Chem; 2018 Nov; 66(44):11812-11822. PubMed ID: 30339011
[TBL] [Abstract][Full Text] [Related]
19. Strategies for improving the functionality of an affinity bioreactor.
Wang T; Yang Z; Emregul E; David A; Balthasar JP; Liang J; Yang VC
Int J Pharm; 2005 Dec; 306(1-2):132-41. PubMed ID: 16246511
[TBL] [Abstract][Full Text] [Related]
20. Serum albumin-protamine conjugate for biocompatible platform for targeted delivery of therapeutic macromolecules.
Absar S; Nahar K; Choi S; Ahsan F; Yang VC; Kwon YM
J Biomed Mater Res A; 2014 Aug; 102(8):2481-90. PubMed ID: 23946132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
